Solural Pharma ApS spin-out technology and together with Østjysk Innovation A/S form a new company Oncoral Pharma ApS with the purpose to develop a new tablet treatment of an existing intravenous chemotheraphy.
- New patent acquisition agreement November 16, 2022
- New Eurasia patent December 25, 2020
- New Manufacturing Authorisation December 18, 2020
If you are interested in joining Solural Pharma ApS, we are seeking professionals, technicians and consultants with expertise within drug development. Please contact
email@example.com for more information about available positions.